Facial Cellulitis Antibiotic Treatment
For facial cellulitis without purulent drainage, start with a beta-lactam antibiotic targeting beta-hemolytic streptococci—specifically cephalexin 500 mg PO four times daily or amoxicillin 500 mg PO three times daily for 5-10 days. 1, 2
Treatment Algorithm Based on Clinical Presentation
Step 1: Determine if Cellulitis is Purulent or Nonpurulent
Nonpurulent cellulitis (no drainage, no abscess—most common on face):
- First-line: Beta-lactam antibiotics targeting streptococci 1, 2
- Cephalexin 500 mg PO QID, OR
- Amoxicillin 500 mg PO TID
- Duration: 5-10 days based on clinical response 1, 2
Purulent cellulitis (with drainage but no drainable abscess):
Step 2: Special Considerations for Facial Location
The face is specifically designated as an "area difficult to drain" requiring antibiotic therapy even for abscesses 2. This anatomic location warrants:
- Lower threshold for antibiotic treatment
- Consider hospitalization if systemic signs present
- Monitor closely for complications given proximity to critical structures
Step 3: When to Add MRSA Coverage
Add MRSA coverage to your initial regimen if ANY of the following are present 1, 2, 3:
- Systemic toxicity (fever, tachycardia, hypotension)
- Failure to respond to beta-lactam within 48-72 hours
- Purulent drainage present
- Known MRSA colonization
- Injection drug use
- Penetrating trauma
Step 4: When to Hospitalize
Admit for IV antibiotics if 2, 3:
- Signs of systemic illness (SIRS criteria)
- Rapid progression despite oral therapy
- Immunocompromised state
- Extremes of age with severe infection
- Concern for deeper/necrotizing infection
IV options for hospitalized patients:
- Vancomycin 15-20 mg/kg/dose IV every 8-12 hours (first-line) 2, OR
- Cefazolin for nonpurulent cellulitis (switch to MRSA coverage if no response) 2
Critical Pitfalls to Avoid
Do NOT routinely cover MRSA for simple nonpurulent facial cellulitis. The IDSA guidelines explicitly state that empirical streptococcal coverage is recommended for nonpurulent cellulitis, with MRSA coverage reserved for treatment failures or systemic toxicity 1, 2. Despite rising community-acquired MRSA rates, beta-hemolytic streptococci remain the primary pathogen in nonpurulent cellulitis 4.
Avoid TMP-SMX or doxycycline monotherapy for nonpurulent cellulitis—these agents have poor activity against streptococci and will miss the most likely pathogen 2. If using these for MRSA coverage, you MUST add a beta-lactam 2.
Do not use rifampin as monotherapy or adjunctive therapy—it provides no benefit and risks resistance 1, 2.
Evidence Quality and Nuances
The IDSA guidelines 1, 2 represent the highest quality evidence available, though they date from 2011. These recommendations are based on strong consensus (A-II level evidence) and remain the standard of care. The distinction between purulent and nonpurulent cellulitis is critical for appropriate antibiotic selection.
Research evidence supports that oral antibiotics are as effective as IV therapy for uncomplicated cellulitis 5, and that beta-lactams remain highly effective in most settings 4. One study from Hawaii with high MRSA prevalence showed TMP-SMX outperformed cephalexin 6, but this contradicts guideline recommendations and likely reflects a purulent cellulitis population or local epidemiology—stick with beta-lactams for typical nonpurulent facial cellulitis unless there are specific risk factors for MRSA.
The 2014 IDSA update 3 reinforces these principles and emphasizes that most cellulitis does not require MRSA coverage initially, with treatment duration of 5 days being sufficient if clinical improvement occurs.